Equities research analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report earnings of ($0.91) per share for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings. The lowest EPS estimate is ($2.20) and the highest is $0.91. Ultragenyx Pharmaceutical reported earnings of ($1.63) per share in the same quarter last year, which would indicate a positive year over year growth rate of 44.2%. The firm is expected to issue its next quarterly earnings results on Thursday, May 3rd.
On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.25) per share for the current year, with EPS estimates ranging from ($8.73) to ($2.54). For the next year, analysts anticipate that the business will post earnings of ($6.61) per share, with EPS estimates ranging from ($8.41) to ($5.20). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.27). The business had revenue of $2.41 million during the quarter, compared to analysts’ expectations of $0.75 million. During the same quarter in the previous year, the business posted ($1.75) earnings per share.
Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $50.00 on Monday. The firm has a market capitalization of $2,480.29, a P/E ratio of -7.03 and a beta of 1.93. Ultragenyx Pharmaceutical has a 12-month low of $41.67 and a 12-month high of $72.38.
Several large investors have recently modified their holdings of the company. California Public Employees Retirement System boosted its holdings in shares of Ultragenyx Pharmaceutical by 3.1% during the third quarter. California Public Employees Retirement System now owns 40,300 shares of the biopharmaceutical company’s stock worth $2,146,000 after acquiring an additional 1,200 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 6.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock valued at $1,237,000 after buying an additional 1,636 shares during the period. Jane Street Group LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 26.1% in the fourth quarter. Jane Street Group LLC now owns 8,821 shares of the biopharmaceutical company’s stock valued at $409,000 after buying an additional 1,828 shares during the period. American International Group Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 8.1% in the third quarter. American International Group Inc. now owns 26,537 shares of the biopharmaceutical company’s stock valued at $1,413,000 after buying an additional 1,984 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its stake in shares of Ultragenyx Pharmaceutical by 11.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 19,098 shares of the biopharmaceutical company’s stock valued at $885,000 after buying an additional 2,000 shares during the period. Institutional investors own 87.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3301724/zacks-analysts-anticipate-ultragenyx-pharmaceutical-inc-rare-will-announce-earnings-of-0-91-per-share.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.